Search publications associated with BioLINCC resources

Reset

Additional Filters

YYYY-MM-DD to YYYY-MM-DD

Table Display Options Select Display Fields

Add or remove columns from the table.

Add/Remove Columns

Found 155 results in 20 millisecondsExport these results
Citation (Ascending)
Shah HS, McGill JB, Hirsch IB, Wu C, Galecki A, de Boer IH, Mauer M, Doria A. Poor glycemic control is associated with more rapid kidney function decline after the onset of diabetic kidney disease. J Clin Endocrinol Metab 2024 Jan 23. Epub 2024 Jan 23.
Shao H, Fonseca V, Stoecker C, Liu S, Shi L. Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO). Pharmacoeconomics 2018 Sep;36(9):1125-1134.
Shao H, Yang S, Fonseca V, Stoecker C, Shi L. Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation. Pharmacoeconomics 2019 Jul;37(7):921-929.
Sheng CS, Miao Y, Ding L, Cheng Y, Wang D, Yang Y, Tian J. Prognostic significance of visit-to-visit variability, and maximum and minimum LDL cholesterol in diabetes mellitus. Lipids Health Dis 2022 Feb 10;21(1):19.
Sheng CS, Tian J, Miao Y, Cheng Y, Yang Y, Reaven PD, Bloomgarden ZT, Ning G. Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial. Diabetes Care 2020 Jun;43(6):1185-1190. Epub 2020 Mar 30.
Shi S, Gouskova N, Najafzadeh M, Wei LJ, Kim DH. Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial. BMJ Open 2021 Sep 13;11(9):e050335.
Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 2015 Jan;3(1):43-51. Epub 2014 Oct 22.
Singleton MJ, German CA, Bertoni AG, Ambrosius WT, Bhave PD, Soliman EZ, Yeboah J. Association of Silent Myocardial Infarction With Major Cardiovascular Events in Diabetes: The ACCORD Trial. Diabetes Care 2020 Apr;43(4):e45-e46.
Singleton MJ, German CA, Soliman EZ, Whalen SP, Bhave PD, Bertoni AG, Yeboah J. Body Mass Index, Sex, and Incident Atrial Fibrillation in Diabetes: The ACCORD Trial. JACC Clin Electrophysiol 2020 Dec 14;6(13):1713-1720. Epub 2020 Oct 28.
Singleton MJ, Soliman EZ, Bertoni AG, Whalen SP, Bhave PD, Yeboah J. Effect of Intensive Glycemic and Blood Pressure Control on QT Prolongation in Diabetes: The ACCORD Trial. Diabetes 2020 Oct;69(10):2186-2193. Epub 2020 Jul 30.
Smith SM, Gurka MJ, Calhoun DA, Gong Y, Pepine CJ, Cooper-DeHoff RM. Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. Am J Med 2018 Dec;131(12):1463-1472.e7. Epub 2018 Aug 22.
Smith SM, Gurka MJ, Winterstein AG, Handberg E, Pepine CJ, Cooper-DeHoff RM. Redefining Resistant Hypertension: A Comparison of Cardiovascular Risk Associated With the 2018 Versus 2008 American Heart Association Definitions for Resistant Hypertension. Circ Cardiovasc Qual Outcomes 2020 Feb;13(2):e005979. Epub 2020 Feb 3.
Smith SM, Gurka MJ, Winterstein AG, Pepine CJ, Cooper-DeHoff RM. Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering. J Clin Hypertens (Greenwich) 2019 Jun;21(6):825-834. Epub 2019 May 7.
Smith SM, Winterstein AG, Pepine CJ, Cooper-DeHoff RM. Thiazide Exposure and Cardiovascular Risk in Type 2 Diabetes Mellitus: A Point of Clarification. Hypertension 2020 Mar;75(3):e2-e5. Epub 2020 Feb 3.
Smith SM. The Reply. Am J Med 2019 Jul;132(7):e624-e625.
Found 155 results in 20 millisecondsExport these results